Association Between Bone Mineral Density and the Use of Nonsteroidal Anti-Inflammatory Drugs and Aspirin: Impact of Cyclooxygenase Selectivity

Journal of Bone and Mineral Research

Volumn 18, Issue 10, 2003, Pages 1795-1802

  Carbone, Laura D ^a   Tylavsky, Francesa A ^a   Cauley, Jane A ^b   Harris, Tamara B ^c   Lang, Thomas F ^d   Bauer, Douglas C ^e   Barrow, Karen D ^a   Kritchevsky, Stephen B ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c Epidemiol   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aspirin; Bone; Cyclo oxygenase; Elderly; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CALCIUM; CELECOXIB; CHOLINE MAGNESIUM TRISALICYLATE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; KETOPROFEN; MECLOFENAMATE SODIUM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SALICYLAMIDE; SALSALATE; SULINDAC; TOLMETIN; VITAMIN D;

AGE; AGED; ARTICLE; BONE DENSITY; COVARIANCE; ENZYME INHIBITION; FEMALE; GENDER; HEIGHT; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; RACE; RHEUMATOID ARTHRITIS; SMOKING; VITAMIN SUPPLEMENTATION; WEIGHT;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BONE AND BONES; BONE DENSITY; COHORT STUDIES; FEMALE; HIP; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PROTEIN ISOFORMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0142241134     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.10.1795     Document Type: Article

References (43)

1. Raisz L 1995 Physiologic and pathologic roles of prostaglandins and other eicosanoids in bone metabolism. J Nutr 125:2024S-2027S.
2. Woodiel FN, Fall PM, Raisz LG 1996 Anabolic effects of prostaglandins in cultured fetal rat calvariae: Structure-activity relations and signal transduction pathway. J Bone Miner Res 11:1249-1255.
3. Jee WS, Ma YF 1997 The in vivo anabolic actions of prostaglandins in bone. Bone 21:297-304.
4. Faye-Petersen OM, Johnson WH Jr, Carlo WA, Hedlund GL, Pacifico AD, Blair HC 1996 Prostaglandin E1-induced hyperostosis: Clinicopathologic correlations and possible pathogenetic mechanisms. Pediatr Pathol Lab Med 16:489-507.
5. Raisz LG, Pilbeam CC, Fall PM 1993 Prostaglandins: Mechanisms of action and regulation of production in bone. Osteoporos Int 3:136-140.
6. Raisz LG 2001 Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am J Med 110:43S-45S.
7. Tai H, Miyaura C, Pilbeam CC, Tamura T, Ohsugi Y, Koishihara Y, Kubodera N, Kawaguchi H, Raisz LG, Suda T 1997 Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation. Endocrinology 138: 2372-2379.
8. Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D, Pick S, Trzaskos JM 1994 Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA 91:11202-11206.
9. Kudo I, Murakami M, Hara S, Inoue K 1993 Mammalian non-pancreatic phospholipases A2. Biochim Biophys Acta 1170:217-231.
10. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM 1993 Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 268:9049-9054.
11. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K 1994 Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and non-ulcerogenic. Proc Natl Acad Sci USA 91:3228-3232.
12. Amin AR, Attur MG, Pillinger M, Abramson SB 1999 The pleiotropic functions of aspirin: Mechanisms of action. Cell Mol Life Sci 15:305-312.
13. Quaedackers ME, Van Den Brink CE, Wissink S, Schreurs RH, Gustafsson JKJA, Van Der Saag PT, Van Der Burg BB 2001 4-hydroxytamoxifen trans-represses nuclear factor-kappa B activity in human osteoblastic U2-OS cells through estrogen receptor (ER)alpha, and not through ER beta. Endocrinology 142:1156-1166.
14. Armour KE, Van'T Hof RJ, Grabowski PS, Reid DM, Ralston SH 1999 Evidence for a pathogenic role of nitric oxide in inflammation-induced osteoporosis. J Bone Miner Res 14:2137-2142.
15. Bauer DC, Orwoll ES, Fox KM, Vogt TM, Lane NE, Hochberg MC, Stone K, Nevitt MC 1996 Aspirin and NSAID use in older women: Effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:29-35.
16. Morton DJ, Barrett-Connor EL, Schneider DL 1998 Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: The Rancho Bernardo Study. J Bone Miner Res 13:1924-1931.
17. Lane NE, Bauer DC, Nevitt MC, Pressman AR, Cummings SR 1997 Aspirin and nonsteroidal anti-inflammatory drug use in elderly women: Effects on a marker of bone resorption. The Study of Osteoporotic Fractures Research Group. J Rheumatol 24:1132-1136.
18. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P 1994 Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 10:405-411.
19. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Creminon C, Maclouf J 1994 Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271:1705-1712.
20. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, Chan CC 1996 A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45:68-74.
21. Cryer B, Feldman M 1998 Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104:413-421.
22. Feldman M, McMahon AT 2000 Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 132:134-143.
23. Vane JR 1971 Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232-235.
24. Abate A, Yang G, Dennery PA, Oberle S, Schroder H 2000 Synergistic inhibition of cyclooxygenase-2 expression by vitamin E and aspirin. Free Radic Biol Med 29:1135-1142.
25. Bellamy N 1995 WOMAC Osteoarthritis Index. A User's Guide. University of Western Ontario, Ontario, Canada.
26. Okada Y, Lorenzo JA, Freeman AM, Tomita M, Morham SG, Raisz LG, Pilbeam CC 2000 Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest 105:823-832.
27. Chiang N, Takano T, Clish CB, Petasis NA, Tai HH, Serhan CN 1998 Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: Development of a specific 15-epi-LXA4 ELISA. J Pharmacol Exp Ther 287: 779-790.
28. Claria J, Serhan CN 1995 Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 92:9475-9479.
29. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA 2001 Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809-1817.
30. Mukherjee D, Nissen SE, Topol EJ 2001 Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954-959.
31. Lang TF, Li J, Harris ST, Genant HK 1999 Assessment of vertebral bone mineral density using volumetric quantitative CT. J Comput Assist Tomogr 23:130-137.
32. Looker AC, Beck TJ, Orwoll ES 2001 Does body size account for gender differences in femur bone density and geometry? J Bone Miner Res 16:1291-1299.
33. Yu W, Gluer CC, Fuerst T, Grampp S, Li J, Lu Y, Genant HK 1995 Influence of degenerative joint disease on spinal bone mineral measurements in postmenopausal women. Calcif Tissue Int 57: 169-174.
34. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443.
35. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR 1999 Nonsteroidal drug selectivities for cyclooxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA 96:7563-7568.
36. Stewart A, Black AJ 2000 Bone mineral density in osteoarthritis. Curr Opin Rheumatol 12:464-467.
37. Pluijm SM, Visser M, Smit JH, Popp-Snijders C, Roos JC, Lips P 2001 Determinants of bone mineral density in older men and women: Body composition as mediator. J Bone Miner Res 16: 2142-2151.
38. Gluer CC, Reiser UJ, Davis CA, Rutt BK. Genant HK 1988 Vertebral mineral determination by quantitative computed tomography (QCT): Accuracy of single and dual energy measurements. J Comput Assist Tomogr 12:242-258.
39. Hangartner TN, Gilsanz V 1996 Evaluation of cortical bone by computed tomography. J Bone Miner Res 11:1518-1525.
40. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM 1993 Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 341:72-75.
41. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91.
42. Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109:267-276.
43. Ettinger B. Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645.